Look beyond the purchase price
Access to a regenerative treatment includes evidence, qualified care, follow-up, and affordability. A service is not meaningfully accessible merely because someone can pay for an initial procedure. People also need understandable information, a suitable clinical setting, and a plan for what happens afterward, including if the result is disappointing or complications occur.
Discuss access only after identifying what the treatment has been shown to do. A speculative longevity benefit should not be treated as a proven advantage that only wealthy people can buy. Equity matters in research and care, but the argument becomes misleading when it assumes an unestablished intervention already works.
Define an equitable path to care
Once a benefit is demonstrated for a particular use, practical barriers become concrete. Travel, time away from work, caring responsibilities, language, and the availability of specialist follow-up may shape who can participate. Addressing only the product price can leave these other barriers unchanged and the intended population underserved.
Patient involvement can help reveal which barriers matter most. Ask people to describe the full journey from referral to follow-up. Include those who could not complete that journey, rather than learning only from those who successfully reached the service. Their experience may expose assumptions in how access was designed.
An equitable plan should state who is eligible, how decisions are made, what support is provided, and how outcomes are monitored. It should also preserve the freedom to decline. Fair access means a genuine option with understandable tradeoffs, not pressure to adopt a technology in order to be considered responsible about aging.